TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31666828
Drug: Control (Lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Lidocaine 1.5% + Triamcinolone 40 mg/ml)
Study: 27348904
Drug: Acupoint embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint embedding therapy applied to Ganshu (BL 18), Tai‐chong (LR 3), Fenglong (ST 40), Zusanli (ST 36), and Sanyinjiao (SP 6), once every 7 days for 6 months.
Study: 27348904
Drug: Acupoint embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint embedding therapy group
Study: 27348904
Drug: Polyene phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene phosphatidylcholine capsules (essentiale), 228 mg/capsule, 2 capsules three times a day for 6 months.
Study: 7009441
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg/day
Study: 1095133
Drug: Aspirin soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin soluble 4 g/day
Study: 1095133
Drug: Indomethacin and
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin and aspirin taken together
Study: 18480831
Drug: Central augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central augmentation index (CAI%)
Study: 10772429
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg qd x 5 d)
Study: 20962623
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day (started 3 days before coronary angiography)
Study: 26516142
Drug: Chronic statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic statin therapy
Study: 17396251
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/day for 14 days (group A2)
Study: 17396251
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (B1 and B2) receiving only pain-relieving therapy
Study: 16223069
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity comprehensive behavioral treatment based on motivational interviewing and Cognitive Behavioral Therapy
Study: 16223069
Drug: Standardized abstinence-oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized abstinence-oriented treatment
Study: 7617248
Drug: Cefotetan (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (average daily dose of 4 g in half of the cases and 6 g in the others, average treatment period of 8 days)
Study: 3567124
Drug: Meptazinol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (1.5 mg/kg)
Study: 3906942
Drug: Pethidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (1.5 mg/kg)
Study: 29203068
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing intervals
Study: 22695185
Drug: EGb-761 (Ginkgo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb-761 (Ginkgo biloba) 240 mg per day for 12 weeks
Study: 20521321
Drug: water plus
Normalized name: Premium Gripe Water Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: water plus 75 mg of caffeine
Study: 9239586
Drug: Propofol Patient-Controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol Patient-Controlled Sedation (PCS) - 0.5 mg/kg, lockout interval 3 min
Study: 11421505
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler (MDI) with terbutaline 1.5 mg (six puffs) and ipratropium 120 microg (six puffs) via six tidal breaths
Study: 30132426
Drug: SAM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM treatment plus flocculent/disinfectant water treatment
Study: 30132426
Drug: SAM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM treatment plus chlorine disinfectant
Study: 30132426
Drug: SAM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM treatment plus ceramic water filter
Study: 30132426
Drug: Standard SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SAM treatment
Study: 20429742
Drug: Corset treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corset treatment (A)
Study: 20429742
Drug: No corset
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corset treatment (B)
Study: 17267922
Drug: Drugs approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs approved by the EMEA for psychiatric disorders
Study: 7863823
Drug: Short-term rhGH
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term rhGH treatment (1 week)
Study: 25201887
Drug: Low-dose fish
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fish oil (3 capsules/day, 1080 mg eicosapentaenoic acid + docosahexaenoic acid)
Study: 26283657
Drug: Low-dose fish
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fish oil
Study: 26283657
Drug: High-dose fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fish oil
Study: 17362279
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 25 mg taken 1-2 hours before sexual activity for 8 weeks
Study: 7075121
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of naproxen daily
Study: 7075121
Drug: Naproxen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (all doses)
Study: 31582358
Drug: hIVIG (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hIVIG (0.25 g/kg bodyweight, 500 mL infusion)
Study: 28902127
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (forced treadmill exercise)
Study: 23708326
Drug: BCAA granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA granules (Livact, 12 g/day) for 60 months
Study: 20684955
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg two times per day
Study: 15001611
Drug: Phytoestrogens (114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogens (114 mg of isoflavonoids)
Study: 9041098
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (0.625 mg per day)
Study: 9041098
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen + medroxyprogesterone acetate (2.5 mg daily)
Study: 9041098
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.1 mg per day)
Study: 30431378
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment (vitamin E, orlistat, pioglitazone hydrochloride, atorvastatin, lisinopril, benzodiazepines, anti-inflammatory agents)
Study: 27633647
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% cream
Study: 8436146
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg t.i.d.
Study: 19699868
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg, titrated to 50 mg daily
Study: 15566510
Drug: IFN 6
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 6 million units (MU) monotherapy (N=30)
Study: 15566510
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ribavirin and IFN 3 MU (N=30)
Study: 9238624
Drug: PUFA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA supplementation (3.4 g daily for 12 months)
Study: 29570536
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training with low-dose testosterone (ExT)
Study: 29570536
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (Ex) and Exercise training with low-dose testosterone (ExT)
Study: 20581300
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy for high-grade osteosarcoma
Study: 20581300
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy for low-grade or periosteal sarcomas with high-grade disease
Study: 20581300
Drug: RT followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT followed by adjuvant chemotherapy for unresectable sarcomas
Study: 20581300
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy for relapsed or refractory disease
Study: 20581300
Drug: Multiagent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent chemotherapy regimens for neoadjuvant and adjuvant treatment
Study: 12444514
Drug: Intraarticular 20
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular 20 mg of tenoxicam in 20 ml normal saline (Group T)
Study: 7677678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of symphysiofundal height and fetal abdominal circumference measurement
Study: 7015492
Drug: 3% carbachol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% carbachol ophthalmic solution
Study: 17618750
Drug: Repeated courses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated courses of antenatal steroids
Study: 17618750
Drug: Single course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single course of antenatal steroids
Study: 19327618
Drug: AAV1/SERCA2a (intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV1/SERCA2a (intracoronary infusion, doses ranging from 1.4 x 10(11) to 3 x 10(12) DNase resistant particles per patient)
Study: 9141211
Drug: Syringe and
Normalized name: KIT, SYRINGE AND TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe and needle administration of hepatitis B vaccine (Engerix‐B)
Study: 30413829
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy
Study: 15881488
Drug: Sulfonylurea monotherapy
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea monotherapy
Study: 24089540
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus sulfonylurea
Study: 19548439
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) combined with transcatheter arterial chemoembolization (TACE)
Study: 18069097
Drug: RTS,S/AS02A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02A vaccine
Study: 8674803
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) for 2 weeks
Study: 6524612
Drug: Prostaglandin-inhibitor naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin-inhibitor naproxen
Study: 21847570
Drug: β-blocker propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker propranolol
Study: 19172143
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine (1.5 mg/kg)
Study: 19172143
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine (1 mg/kg)
Study: 12199319
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (25,000, 50,000, and 75,000 IU daily for one year)
Study: 7597378
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid preparation (placebo)
Study: 1978947
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms budesonide daily
Study: 1978947
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms budesonide daily
Study: 8877232
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (control)
Study: 17520441
Drug: Fast-dissolving lyophilized
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fast-dissolving lyophilized tablet (LT)
Study: 17520441
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablet (IR)
Study: 11915777
Drug: 3-day fasting
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day fasting with daily training activities
Study: 31035054
Drug: Danhong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong injection (DHI)
Study: 22819912
Drug: pegylated IFN‐α2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated IFN‐α2a (180 mcg/week) plus ribavirin (1000‐1200 mg/day) and amantadine (200mg/day) for 48 weeks
Study: 17377767
Drug: Surfactant administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administration (n=8)
Study: 9468207
Drug: Sibrafiban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban (5 mg daily to 10 mg twice daily for 28 days)
Study: 9468207
Drug: Sibrafiban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban (5 mg twice daily to 15 mg once daily for 28 days)
Study: 9468207
Drug: Sibrafiban (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban (various doses)
Study: 9468207
Drug: Aspirin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (for 28 days)
Study: 7892866
Drug: Antenatal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal steroids
Study: 7892866
Drug: Cesarean section
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cesarean section delivery with antenatal steroids
Study: 22317851
Drug: Infiltration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration of lidocaine plus 40 mg methylprednisolone acetate
Study: 19875309
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ramipril 24 hours before surgery (Group A)
Study: 17828093
Drug: Gel Metrogil
Normalized name: metronidazole Topical Gel [MetroGel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel Metrogil Denta and toothpaste Mexidol Dent aktiv
Study: 7856526
Drug: gemfibrozil (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (1,200 mg/day)
Study: 21868369
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin
Study: 2228058
Drug: Centperazine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centperazine (300 mg/day)
Study: 375449
Drug: Reserpine and
Normalized name: reserpine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine and kanamycin treatment
Study: 31205182
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (Op)
Study: 31205182
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (NonOp)
Study: 28133925
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg intravenously on days 1, 15, 29, and week 8)
Study: 23989945
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment
Study: 21196806
Drug: Day hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day hospital treatment
Study: 17616536
Drug: Fludrocortisone acetate
Normalized name: Fludrocortisone Acetate
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fludrocortisone acetate (FCA) 0.1 mg/d
Study: 15775731
Drug: Unopposed transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed transdermal 17beta‐estradiol and MPA
Study: 11334901
Drug: HRT (Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (Hormone Replacement Therapy)
Study: 12066081
Drug: Granuflex improved
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granuflex improved formulation (Convatec, UK)
Study: 23157935
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet (4.1 g [105 mEq] potassium/2,100 kcal/d)
Study: 23157935
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (1.7 g [43 mEq] potassium/2,100 kcal/d)
Study: 19032700
Drug: Structured psychoeducational
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured psychoeducational intervention (n = 38) consisting of monthly sessions for 9 months
Study: 16409530
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg/kg i.v. before induction of general anesthesia
Study: 16409530
Drug: Ilioinguinal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal and iliohypogastric nerve block with 0.5% bupivacaine (0.25 ml/kg) before skin incision
Study: 14974267
Drug: New preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New preparation for wound edge protection
Study: 7978588
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg)
Study: 10793878
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg/NETA 0.5 mg
Study: 27287856
Drug: Erlotinib 85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 85 mg/m2 daily
Study: 27287856
Drug: Etoposide 50
Normalized name: etoposide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide 50 mg/m2/day for 21 days
Study: 20594372
Drug: Subsidized artemisinin-based
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsidized artemisinin-based combination therapies (ACTs)
Study: 18238985
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant pelvic radiation therapy
Study: 18238985
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for childbearing
Study: 12571693
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of acetylsalicylic acid
Study: 12571693
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of angiotensin-converting enzyme inhibitors
Study: 12571693
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of thrombolytics
Study: 10491502
Drug: Effidrate cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effidrate cream (glycerol alkyl-ether) applied on one side of the face
Study: 1671008
Drug: Propranolol-atropine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol-atropine infusion
Study: 30973204
Drug: Basal insulin-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal insulin-supported oral antidiabetic drugs therapy (BOT)
Study: 27453733
Drug: Oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic drugs (OADs)
Study: 15159318
Drug: Controlled diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled diet with 5 servings (750 g) of fruits and vegetables daily
Study: 15159318
Drug: Controlled diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled diet with 2 servings (300 g) of fruits and vegetables daily
Study: 8528169
Drug: Melphalan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan (200 mg/m2) and methylprednisolone (1.5 g x 5) for conditioning
Study: 7321973
Drug: Hydroalcoholic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroalcoholic preparation (Brondecon elixir)
Study: 7321973
Drug: Alcohol-free preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-free preparation (Nuelin syrup)
Study: 7321973
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both preparations
Study: 31658542
Drug: Micro-negative pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-negative pressure treatment
Study: 27925676
Drug: Carfilzomib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib at doses ranging from 15 to 20/56 mg/m2, administered as an intravenous infusion on 2 consecutive days each week for 3 weeks (days 1, 2, 8, 9, 15, and 16).
Study: 27925676
Drug: Carfilzomib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib at 20/56 mg/m2 as a 30-minute infusion for monotherapy and combination therapy.
Study: 24464530
Drug: Citalopram (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (2 × 20 mg)
Study: 19490626
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (NNS) used hourly (intervention group)
Study: 19490626
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (NNS) used ad libitum (control group)
Study: 15070877
Drug: Lidocaine vaginal
Normalized name: lidocaine Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine vaginal gel
Study: 9659024
Drug: Rate of
Normalized name: Citrate of Magnesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate of injection and volume of local anaesthetic